memantine has been researched along with Agitation, Psychomotor in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to determine whether changes in agitation and aggression would follow memantine treatment and, if so, be associated with changes in nursing burden in institutionalized patients with moderate to severe AD." | 9.15 | Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. ( Cappell, J; Eryavec, GM; Herrmann, N; Lanctôt, KL, 2011) |
| " The current retrospective analysis evaluated the efficacy and safety of memantine in a subpopulation of patients with Alzheimer's disease exhibiting behavioral symptoms of agitation/aggression or psychosis at baseline." | 9.13 | Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. ( Ballard, CG; Cooper, JA; Loft, H; Wilcock, GK, 2008) |
| "To investigate the behavioral effects of memantine in moderate to severe Alzheimer disease (AD)." | 9.12 | Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. ( Cummings, JL; Graham, SM; Schneider, E; Tariot, PN, 2006) |
| "The authors retrospectively reviewed the clinical records of 196 patients with dementia treated with memantine for at least 6 months." | 7.81 | Retrospective study on agitation provoked by memantine in dementia. ( Da Re, F; Isella, V; Rucci, F, 2015) |
| "Three patients with probable dementia with Lewy bodies (DLB) experienced worsening delusions and visual hallucinations as a result of memantine therapy." | 7.73 | Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. ( Josephs, KA; Ridha, BH; Rossor, MN, 2005) |
| "Memantine was significantly better than placebo for cognition." | 6.77 | Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. ( Auestad, BH; Ballard, C; Boustani, M; Coulton, S; Crugel, M; Fox, C; Katona, C; Livingston, G; Maidment, I; Treloar, A, 2012) |
| "Patients with moderate-to-severe AD with Neuropsychiatric Inventory (NPI) total score ≥13 and NPI agitation/aggression score ≥1 were randomized to placebo or 20-mg memantine in a double-blind, 24-week trial." | 5.17 | A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease. ( Boneva, N; Gauthier, S; Herrmann, N; Lemming, OM, 2013) |
| "The aim of the study was to determine whether changes in agitation and aggression would follow memantine treatment and, if so, be associated with changes in nursing burden in institutionalized patients with moderate to severe AD." | 5.15 | Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. ( Cappell, J; Eryavec, GM; Herrmann, N; Lanctôt, KL, 2011) |
| " The current retrospective analysis evaluated the efficacy and safety of memantine in a subpopulation of patients with Alzheimer's disease exhibiting behavioral symptoms of agitation/aggression or psychosis at baseline." | 5.13 | Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. ( Ballard, CG; Cooper, JA; Loft, H; Wilcock, GK, 2008) |
| "To investigate the behavioral effects of memantine in moderate to severe Alzheimer disease (AD)." | 5.12 | Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. ( Cummings, JL; Graham, SM; Schneider, E; Tariot, PN, 2006) |
| "The authors retrospectively reviewed the clinical records of 196 patients with dementia treated with memantine for at least 6 months." | 3.81 | Retrospective study on agitation provoked by memantine in dementia. ( Da Re, F; Isella, V; Rucci, F, 2015) |
| " This article covers the following topics on caring for patients with dementia in long-term care: (1) the efficacy of cholinesterase inhibitors and memantine, (2) the optimal environment for maintenance of function in moderate dementia, (3) the treatment of depression and agitation, and (4) the evaluation and management of eating problems." | 3.77 | Managing the patient with dementia in long-term care. ( Castillo, EH; Cheng, H; Fulton, AT; Rhodes-Kropf, J, 2011) |
| "Three patients with probable dementia with Lewy bodies (DLB) experienced worsening delusions and visual hallucinations as a result of memantine therapy." | 3.73 | Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. ( Josephs, KA; Ridha, BH; Rossor, MN, 2005) |
| "Memantine was significantly better than placebo for cognition." | 2.77 | Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. ( Auestad, BH; Ballard, C; Boustani, M; Coulton, S; Crugel, M; Fox, C; Katona, C; Livingston, G; Maidment, I; Treloar, A, 2012) |
| "Dementia is a risk factor for delirium, and their symptoms can be similar." | 2.72 | Chronic Brain Failure. ( Wolak, JP, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 11 (64.71) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Wolak, JP | 1 |
| Yu, EY | 1 |
| Liao, ZL | 1 |
| Tan, YF | 1 |
| Qiu, YJ | 1 |
| Zhu, JP | 1 |
| Chen, Y | 1 |
| Lin, SS | 1 |
| Wu, MH | 1 |
| Herrmann, N | 2 |
| Gauthier, S | 1 |
| Boneva, N | 1 |
| Lemming, OM | 1 |
| Borre, YE | 1 |
| Panagaki, T | 1 |
| Koelink, PJ | 1 |
| Morgan, ME | 1 |
| Hendriksen, H | 1 |
| Garssen, J | 1 |
| Kraneveld, AD | 1 |
| Olivier, B | 1 |
| Oosting, RS | 1 |
| Gabryelewicz, T | 1 |
| Da Re, F | 1 |
| Rucci, F | 1 |
| Isella, V | 1 |
| Ballard, C | 3 |
| Thomas, A | 1 |
| Gerry, S | 1 |
| Yu, LM | 1 |
| Aarsland, D | 2 |
| Merritt, C | 1 |
| Corbett, A | 2 |
| Davison, C | 1 |
| Sharma, N | 1 |
| Khan, Z | 1 |
| Creese, B | 1 |
| Loughlin, P | 1 |
| Bannister, C | 1 |
| Burns, A | 1 |
| Win, SN | 1 |
| Walker, Z | 1 |
| Yoon, SJ | 1 |
| Choi, SH | 1 |
| Na, HR | 1 |
| Park, KW | 1 |
| Kim, EJ | 1 |
| Han, HJ | 1 |
| Lee, JH | 1 |
| Shim, YS | 1 |
| Na, DL | 1 |
| Chitramohan, R | 1 |
| Osborn, GG | 1 |
| Saunders, AV | 1 |
| Cappell, J | 1 |
| Eryavec, GM | 1 |
| Lanctôt, KL | 1 |
| Rhodes-Kropf, J | 1 |
| Cheng, H | 1 |
| Castillo, EH | 1 |
| Fulton, AT | 1 |
| Fox, C | 1 |
| Crugel, M | 1 |
| Maidment, I | 1 |
| Auestad, BH | 1 |
| Coulton, S | 1 |
| Treloar, A | 1 |
| Boustani, M | 1 |
| Katona, C | 1 |
| Livingston, G | 1 |
| Ridha, BH | 1 |
| Josephs, KA | 1 |
| Rossor, MN | 1 |
| Cummings, JL | 1 |
| Schneider, E | 1 |
| Tariot, PN | 1 |
| Graham, SM | 1 |
| Monastero, R | 1 |
| Camarda, C | 1 |
| Pipia, C | 1 |
| Camarda, R | 1 |
| Wilcock, GK | 1 |
| Ballard, CG | 1 |
| Cooper, JA | 1 |
| Loft, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double-Blind, Parallel-Group Study Examining the Efficacy and Safety of Memantine in Patients With Moderate to Severe Dementia of the Alzheimer's Type[NCT00857649] | Phase 3 | 369 participants (Actual) | Interventional | 2003-12-31 | Terminated | ||
| Phase IV-An Open-Label Prospective Study of Memantine in Institutionalized Patients With Severe Alzheimer's Disease and Significant Behavioural and Psychological Symptoms of Dementia[NCT00401167] | Phase 4 | 32 participants (Anticipated) | Interventional | 2006-11-30 | Completed | ||
| Pragmatic Randomized Control Trial of Memantine For Agitation In Dementia[NCT00371059] | Phase 4 | 153 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change from Baseline in Neuropsychiatric Inventory (NPI) total score.~NPI is a validated scale that assesses behavioural disturbances in patients with dementia. The 12 item version consists of 10 behavioural and 2 neurovegetative areas. It provides both a total score as well as scores for a number of sub-scales. The frequency, severity and caregiver distress for each domain are measured. The NPI is based upon responses obtained from the caregiver. The total score is from 0 to 144. A higher score reflects more frequency and severity of the disturbances." (NCT00857649)
Timeframe: Baseline to Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Memantine | -3.90 |
| Placebo | -5.13 |
"Change from Baseline in Severe Impairment Battery (SIB) total score.~SIB is a validated scale used to assess cognitive function in patients with moderate to severe dementia. Items are single words or one-step commands combined with gestures. Nine domains are assessed, and the total score is between 0 and 100. A lower total score reflects the loss of cognitive function." (NCT00857649)
Timeframe: Baseline to Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Memantine | -2.34 |
| Placebo | -1.86 |
"Change from Baseline on the Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) 19-item version total score.~ADCS-ADL- 19 items version for moderate to severe AD will measure patient's functioning. This battery of ADL questions is used here to measure the functional capabilities of patients with dementia. The inventory is done by interviewing a person in close contact with the patient and covers the most usual and consistent performance of the patient over the preceding 4 weeks. Total score is from 0 to 54. The higher score, the lower impairment." (NCT00857649)
Timeframe: Baseline to Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Memantine | -4.36 |
| Placebo | -2.56 |
"Change from Baseline on the Cohen-Mansfield Agitation Inventory (CMAI) - Long Form total score.~CMAI - Long Form looks specifically at agitated behaviour in patients with cognitive impairment. It is a seven-point rating scale assessing the frequency of up to 29 agitated behaviours, ranging from 1 = Never to 7 = Several times an hour. Rating is based on responses obtained from interviews with the caregiver. The total score ranges from 29 to 203, with a higher score reflecting more frequent behavioural disturbances." (NCT00857649)
Timeframe: Baseline to Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Memantine | -0.26 |
| Placebo | -1.16 |
"Clinician's Interview-Based Impression of Change-Plus Version (CIBIC-plus). Improvement evaluated with reference to Baseline.~CIBIC-plus is a global rating that is derived through an independent, comprehensive interview with the patient and caregiver by a rater who is barred from knowledge of all other psychometric test scores conducted as part of this protocol as well as from reported safety data. The rating is made on a 7-point scale ranging from 1 = marked improvement to 7 = marked worsening. A score of 4 indicates no change." (NCT00857649)
Timeframe: Baseline to Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Memantine | 4.68 |
| Placebo | 4.63 |
4 reviews available for memantine and Agitation, Psychomotor
| Article | Year |
|---|---|
Chronic Brain Failure.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Cholinesterase Inhibitors; Delir | 2021 |
[Pharmacological treatment of behavioral symptoms in dementia patients].
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents; | 2014 |
Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions.
Topics: Aged; Aggression; Alzheimer Disease; Anticonvulsants; Antidepressive Agents, Second-Generation; Anti | 2009 |
Current treatments for patients with Alzheimer disease.
Topics: Aggression; Alzheimer Disease; Behavior Therapy; Cholinesterase Inhibitors; Depression; Excitatory A | 2010 |
8 trials available for memantine and Agitation, Psychomotor
| Article | Year |
|---|---|
[Efficacy and tolerance of Memantine monotherapy and combination therapy with Reinhartdt And Sea Cucumber Capsule on agitation in moderate to severe Alzheimer disease].
Topics: Alzheimer Disease; Animals; Humans; Memantine; Neuropsychological Tests; Psychomotor Agitation; Sea | 2017 |
A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antiparkinson Agents; Double-Blind Method; F | 2013 |
A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cross-Over Studies; Dose-Response | 2015 |
Effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate Alzheimer's disease: a multicenter 24-week prospective randomized open-label study (the Korean EXelon Patch and combination with mEmantine
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Dose-Response Relationship, D | 2017 |
Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study.
Topics: Aggression; Alzheimer Disease; Caregivers; Dopamine Agents; Female; Humans; Long-Term Care; Male; Me | 2011 |
Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Female; Humans; Male; Memantine; Psychomotor A | 2012 |
Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Behavi | 2006 |
Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
Topics: Aged; Aggression; Alzheimer Disease; Delusions; Dopamine Agents; Female; Hallucinations; Humans; Mal | 2008 |
5 other studies available for memantine and Agitation, Psychomotor
| Article | Year |
|---|---|
Neuroprotective and cognitive enhancing effects of a multi-targeted food intervention in an animal model of neurodegeneration and depression.
Topics: Animals; Atrophy; Cell Death; Cognition Disorders; Depressive Disorder; Disease Models, Animal; Hipp | 2014 |
Retrospective study on agitation provoked by memantine in dementia.
Topics: Aged; Aged, 80 and over; Dementia; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantin | 2015 |
Managing the patient with dementia in long-term care.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Depression; Fema | 2011 |
Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine.
Topics: Age of Onset; Aged; Antiparkinson Agents; Brain; Cognition Disorders; Disease Progression; Hallucina | 2005 |
Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases.
Topics: Aged; Alzheimer Disease; Excitatory Amino Acid Antagonists; Female; Hallucinations; Humans; Memantin | 2007 |